Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 79,237 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Active, not recruiting Phase 2 Interventional

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

NCT06745323
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Tarlatamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Plainville, Connecticut • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 4:42 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Exparel vs Block for ACL Reconstruction

NCT06006624
View directory record Official record
Conditions
ACL, Postoperative Pain
Interventions
Exparel 30 mL, 0.5% bupivacaine, Dexamethasone, iPACK block
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

Belimumab in Remission of VASculitis

NCT01663623
View directory record Official record
Conditions
Vasculitis
Interventions
Placebo, Belimumab 10 mg/kg, Azathioprine
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 31, 2026, 4:42 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

NCT04909723
View directory record Official record
Conditions
Healthy Volunteers, Enteric Hyperoxaluria
Interventions
NOV-001, NB1000S, NB2000P, Placebo
Combination Product · Biological · Drug
Lead sponsor
Novome Biotechnologies Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Daytona Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes

NCT00738023
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
Rosiglitazone, Normal saline 0.9%, Intralipid 20%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 31, 2026, 4:42 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH

NCT04280523
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ESR-specific PET scan
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
13 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 31, 2026, 4:42 PM EDT
Active, not recruiting Not applicable Interventional

Improving the Part C Early Intervention Service Delivery System for Children With ASD

NCT05114538
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Reciprocal Imitation Training
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
16 Months to 33 Months
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • East Lansing, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 31, 2026, 4:42 PM EDT
Terminated Phase 1 Interventional

Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies

NCT00526838
View directory record Official record
Conditions
Cancer, Lymphoma
Interventions
XL228
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Results available

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

NCT00785538
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
IMC-A12
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • Detroit, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 31, 2026, 4:42 PM EDT
Terminated Phase 1 Interventional

Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia

NCT00575848
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Glycine, Placebo
Dietary Supplement
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Oct 31, 2026, 4:42 PM EDT
Completed No phase listed Observational

Pharmacoepidemiology and Pharmacogenetics of a Statin Adverse Event

NCT00241748
View directory record Official record
Conditions
Rhabdomyolysis
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
30 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

NCT05357755
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Beverly Hills, California • Skokie, Illinois • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age

NCT01206478
View directory record Official record
Conditions
Chronic Oral Food Refusal
Interventions
Amitriptyline, Placebo, Megestrol
Drug
Lead sponsor
Ann Davis, PhD, MPH, ABPP
Other
Eligibility
9 Months to 8 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
3
States / cities
Kansas City, Kansas • New Orleans, Louisiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of the Hypo-fractionated (Large Doses) Radiation Therapy in Post-menopausal Women With Breast Cancers

NCT02883985
View directory record Official record
Conditions
Breast Cancer
Interventions
6 Gy/ fraction
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Phase 1 Interventional

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

NCT05006885
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
ALT-801, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Tucson, Arizona • Montclair, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Phase 2Phase 3 Interventional

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

NCT05818085
View directory record Official record
Conditions
Gout
Interventions
ABP-671, Allopurinol, Placebo
Drug · Other
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
19 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Tempe, Arizona • Tuscon, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Naproxen Sodium ER Pharmacokinetic Study

NCT00818415
View directory record Official record
Conditions
Pain
Interventions
Naproxen sodium ER (BAYH6689), Commercial Naproxen (Aleve, BAYH6689)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Shared Medical Visits for Spanish-speaking Patients With Type 2 Diabetes

NCT02836015
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Shared Medical Visit
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 31, 2026, 4:42 PM EDT
Terminated Phase 4 Interventional

Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation

NCT06169735
View directory record Official record
Conditions
Parathyroid Dysfunction, Adenoma
Interventions
Indocyanine green, SPY Portable Handheld Imaging
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Environmental Localization Mapping and Guidance for Visual Prosthesis Users

NCT04359108
View directory record Official record
Conditions
Retinitis Pigmentosa, Visual Impairment, Visual Prosthesis
Interventions
Navigation system mode: Argus Vision, Navigation system mode: Depth Vision, Navigation system mode: Depth Vision with Haptic / Audio, Navigation system mode: Haptic / Audio, Navigation system mode: High Field-of-View Depth Vision, Distance test vision mode: Low Resolution / Low Field-of-View, Distance test vision mode: Low Resolution / High Field-of-View, Distance test vision mode: High Resolution / Low Field-of-View, Distance test vision mode: High Resolution / High Field-of-View
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 31, 2026, 4:42 PM EDT
Active, not recruiting Phase 2 Interventional

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

NCT04740476
View directory record Official record
Conditions
Dravet Syndrome
Interventions
zorevunersen (STK-001)
Drug
Lead sponsor
Stoke Therapeutics, Inc
Industry
Eligibility
30 Months and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
17
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

NCT01056276
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bendamustine, Bortezomib, Dexamethasone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
13
States / cities
Thousand Oaks, California • Fort Myers, Florida • Baton Rouge, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Investigation Into a 21-Day Detoxification Diet With a Seven-Day Continuation

NCT05858476
View directory record Official record
Conditions
Detoxification
Interventions
21-Day Detox and Green Drink supplement
Other
Lead sponsor
Chef V, LLC
Industry
Eligibility
31 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 31, 2026, 4:42 PM EDT
Completed Not applicable Interventional

Weight Gain Prevention

NCT00606840
View directory record Official record
Conditions
Weight Gain
Interventions
large changes in eating and activity, small changes in eating and activity
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 31, 2026, 4:42 PM EDT